文献速递类风湿关节炎

生物制剂经治类风湿关节炎进展为难治性RA的多变量预测模型开发与外部验证

Development and External Validation of a Multivariable Predictive Model for Progression to Difficult-to-Treat Rheumatoid Arthritis in Biologic-Experienced Patients.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2025-10-16

研究利用两个大型独立观察性队列开发并外部验证多变量预测模型,识别按EULAR 2021标准定义的难治性类风湿关节炎(D2T-RA)。推导队列700例中113例(16%)发生D2T-RA,验证队列2070例中571例(28%)发生D2T-RA;C指数分别为0.643(95%CI 0.585-0.698)和0.620(95%CI 0.596-0.643),校准提示总体中等预测能力。功能状态恶化、疼痛、疲劳和整体疾病活动度在两队列中均为一致的首要预测因子。

要点

  • 推导队列700例中113例(16%)进展为D2T-RA,验证队列2070例中571例(28%)进展为D2T-RA。
  • 模型C指数推导队列0.643(95%CI 0.585-0.698),验证队列0.620(95%CI 0.596-0.643)。
  • 功能状态恶化、疼痛、疲劳和整体疾病活动度在两队列中均为一致的首要预测因子。

核心结论

  • 模型表现出中等区分度和校准度,凸显准确预测D2T-RA结局的挑战。
  • 作者认为这些发现强调需要进一步研究以提高预测性能,可能通过纳入额外生物标志物实现。

研究设计与样本

  • 使用两个大型独立观察性类风湿关节炎患者队列开发并外部验证多变量预测模型,D2T-RA按EULAR 2021标准定义。
  • 在首次接受生物制剂和/或靶向合成改善病情抗风湿药(b/tsDMARD)治疗的参与者中,采用随机生存森林开发多变量预测模型(推导队列)。
  • 在启动或转换b/tsDMARD治疗的参与者队列中验证模型。
  • 推导队列700例(84%女性,平均年龄55岁,中位随访40个月,113例[16%]发生D2T-RA)。
  • 验证队列2070例(79%女性,平均年龄56岁,中位随访8个月,571例[28%]发生D2T-RA)。

主要发现

  • 推导队列C指数为0.643(95%CI 0.585-0.698),验证队列C指数为0.620(95%CI 0.596-0.643)。
  • 校准指标提示总体中等预测能力。
  • 功能状态恶化、疼痛、疲劳和整体疾病活动度在两队列中均为一致的首要预测因子。

关键数值与推荐

  • D2T-RA采用EULAR 2021标准定义。
  • 推导队列C指数0.643(95%CI 0.585-0.698),验证队列C指数0.620(95%CI 0.596-0.643)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 模型仅表现出中等区分度和校准度,准确预测D2T-RA结局存在挑战。
  • 作者认为需要进一步研究以提高预测性能,可能通过纳入额外生物标志物实现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Approximately 20% of patients with rheumatoid arthritis (RA) cycle through multiple therapies without achieving treatment goals and are classified as having "difficult-to-treat" RA (D2T-RA); however, no risk prediction tools exist to identify which patients are at highest risk. Our aim was to develop and validate a predictive model for progression to D2T-RA among patients with RA. METHODS: We used data from two large independent observational cohorts of patients with RA to develop and externally validate a multivariable prediction model to identify participants at risk of D2T-RA, defined using EULAR 2021 criteria. We developed a multivariable predictive model for D2T-RA using random survival forests in participants treated with their first biologic and/or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) (derivation cohort). We validated the model in a cohort of participants initiating or switching b/tsDMARD therapies. RESULTS: A total of 700 participants were in the derivation cohort (84% female, mean age 55 years, median follow-up 40 months, 113 [16%] with D2T-RA), and 2,070 participants were included in the validation cohort (79% female, mean age 56 years, median follow-up 8 months, 571 [28%] with D2T-RA). We observed C-index values of 0.643 (95% confidence interval [CI] 0.585-0.698; derivation cohort) and 0.620 (95% CI 0.596-0.643; validation cohort). Calibration measures suggested overall moderate predictive ability. Worsened functional status, pain, fatigue, and global disease activity were consistently top predictors across both cohorts. CONCLUSION: Our model demonstrated moderate discrimination and calibration, highlighting the challenge in accurately predicting D2T-RA outcomes. These findings underscore the need for further research to improve predictive performance, potentially through the incorporation of additional biomarkers.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Paudel ML, Shadick N, Weinblatt M, et al. Development and External Validation of a Multivariable Predictive Model for Progression to Difficult-to-Treat Rheumatoid Arthritis in Biologic-Experienced Patients. Arthritis Care Res (Hoboken). 2025. PMID: 40977501. doi:10.1002/acr.25654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。